Table 2 CT features comparison among HPs and GISTs: univariate analysis
CT findings | HPs (n = 48) | GISTs (n = 100) | P value* |
|---|---|---|---|
Location |  |  | < 0.001 |
 The upper part of stomach | 5(10.4%) | 49(49.0%) |  |
 The middle part of stomach | 6(12.5%) | 15(15.0%) |  |
 The lower part of stomach | 25(52.1%) | 17(17.0%) |  |
 Duodenum | 7(14.6%) | 10(10.0%) |  |
 Jejunum or ileum | 5(10.4%) | 9(9.0%) |  |
Multiple lesions | Â | Â | 0.622 |
 No | 45(93.7%) | 97(97.0%) |  |
 Yes | 3(6.3%) | 3(3.0%) |  |
Contour | Â | Â | 0.200 |
 Round | 7(14.6%) | 16(16.0%) |  |
 Ovoid | 15(31.3%) | 49(49.0%) |  |
 Hill-like | 9(18.8%) | 10(10.0%) |  |
 Flat | 7(14.6%) | 8(8.0%) |  |
 Irregular | 10(20.8%) | 17(17.0%) |  |
Imaging type | Â | Â | 0.096 |
 Solid-dominant | 35(72.9%) | 79(79.0%) |  |
 Cystic-dominant | 5(10.4%) | 2(2.0%) |  |
 Mixed | 8(16.7%) | 19(19.0%) |  |
Microlobulated | Â | Â | 0.193 |
 No | 19(39.6%) | 51(51.0%) |  |
 Yes | 29(60.4%) | 49(49.0%) |  |
Calcification | Â | Â | 0.603 |
 No | 46(95.8%) | 92(92.0%) |  |
 Yes | 2(4.2%) | 8(8.0%) |  |
Growth pattern | Â | Â | 0.462 |
 Intraluminal | 21(43.8%) | 44(44.0%) |  |
 Extraluminal | 6(12.5%) | 20(20.0%) |  |
 Mixed | 21(43.8%) | 36(36.0%) |  |
Low intralesional attenuation | Â | Â | 0.791 |
 No | 37(77.1%) | 79(79.0%) |  |
 Yes | 11(22.9%) | 21(21.0%) |  |
Border |  |  | < 0.001 |
 Well-defined | 25(52.1%) | 84(84.0%) |  |
 Ill-defined | 23(47.9%) | 16(16.0%) |  |
Peritumoral hypodensity line | Â | Â | 0.002 |
 No | 40(83.3%) | 58(58.0%) |  |
 Yes | 8(16.7%) | 42(42.0%) |  |
Duct-like structure | Â | Â | 0.002 |
 No | 41(85.4%) | 99(99.0%) |  |
 Yes | 7(14.6%) | 1(1.0%) |  |
Surface ulceration | Â | Â | 0.097 |
 No | 45(93.8%) | 84(84.0%) |  |
 Yes | 3(6.3%) | 16(16.0%) |  |
EVFDM | Â | Â | 0.588 |
 No | 29(60.4%) | 65(65.0%) |  |
 Yes | 19(39.6%) | 35(35.0%) |  |
Hyperenhancement of the overlying mucosa | Â | Â | 0.481 |
 No | 37(77.1%) | 82(82.0%) |  |
 Yes | 11(22.9%) | 18(18.0%) |  |
Peak enhancement phase | Â | Â | 0.256 |
 Arterial phase | 9(18.8%) | 13(13.0%) |  |
 Venous phase | 20(41.7%) | 56(56.0%) |  |
 Both | 19(39.6%) | 31(31.0%) |  |
Enhancement grade | Â | Â | 0.004 |
 Mild | 7(14.6%) | 8(8.0%) |  |
 Moderate | 8(16.7%) | 44(44.0%) |  |
 Strong | 33(68.8%) | 48(48.0%) |  |
Enhancement pattern | Â | Â | 0.008 |
 Heterogeneous | 13(27.1%) | 50(50.0%) |  |
 Homogeneous | 35(72.9%) | 50(50.0%) |  |
LD | 19.71 ± 6.30 | 21.62 ± 6.00 | 0.972 |
SD | 13.69 ± 4.59 | 16.65 ± 4.87 | 0.406 |
LD/SD ratio | 1.50(0.52) | 1.32(0.28) | 0.005 |
HU plain | 44.04(13.94) | 40.93(8.10) | 0.255 |
HU arterial | 86.81(37.48) | 67.54(30.43) | 0.029 |
HU venous | 93.80(26.26) | 81.86(29.65) | 0.052 |
DEAP | 43.54(34.18) | 26.93(32.04) | 0.030 |
DEVP | 50.35(26.30) | 38.72(26.05) | 0.116 |
Enhancement ratio | 1.17(0.66) | 0.99(0.73) | 0.158 |
HU lesion/pancreas, P | 0.88(0.31) | 0.84(0.21) | 0.399 |
HU lesion/pancreas, A | 0.88(0.31) | 0.67(0.20) | 0.006 |
HU lesion/pancreas, V | 1.03(0.23) | 0.90(0.31) | 0.077 |